Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

4.490 -0.860 (-16.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 5 6 7 8 Next >
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
Via ACCESSWIRE
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
Via ACCESSWIRE
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases
Via ACCESSWIRE
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
Via ACCESSWIRE
Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen
Via ACCESSWIRE
Adapsyn Bioscience Inks Collaboration Pact With Evotec
Via Benzinga
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
From Toronto Innovation Acceleration Partners
Via Business Wire
Ford, Evotec And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning after recording gains in the previous session. Here are some big stocks moving lower in today’s pre-market trading session. 
Via Benzinga
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
Via ACCESSWIRE
Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)
Via ACCESSWIRE
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
Via ACCESSWIRE
Twitter, Zoom Video And Some Other Big Stocks Moving Lower On Tuesday
  GigaCloud Technology Inc. (NASDAQ: GCT) fell 29.9% to $29.01 after declining around 14% on Monday. 
Via Benzinga
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
Via ACCESSWIRE
WeTrade, Roblox And Some Other Big Stocks Moving Lower On Wednesday
  OptimizeRx Corporation (NASDAQ: OPRX) shares fell 26.7% to $16.32 after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates. 
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS. 
Via Benzinga
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session
Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380. 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
  
Via Benzinga
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
  Gainers   
Via Benzinga
Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate
Via Benzinga
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing. 
Via Benzinga
Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
Via ACCESSWIRE
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
From Alpine Immune Sciences Inc.
Via Business Wire
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that... 
Via Benzinga
Evotec SE Reports First Half-year 2022 Results on 11 August 2022
Via ACCESSWIRE
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop?
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated 792 million people around the world... 
Via Benzinga
Evotec SE Reports Results of Annual General Meeting 2022
HAMBURG, GERMANY / ACCESSWIRE / June 22, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the... 
From Evotec SE
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Exscientia -Evotec Cancer Therapy Shows Encouraging Action In Healthy Volunteers
Via Benzinga
Evotec Enters a Drug Discovery Collaboration with Janssen
HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen... 
From Evotec SE
Via AccessWire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.